LIVE Price Database Suppliers B2B suppliers Quality & badges Encyclopedia Articles
LONGEVITY TOPICS
NAD+ Precursors Sirtuin Activators Senolytics Autophagy Mitochondrial Hormesis
About PeptideCompare Business Network Contact Policy
Home / Encyclopedia / Khavinson Bioregulators / Suprefort
MONOGRAPH No. 060
EVIDENCE BASELimited
TYPE
Natural peptide complex (cytomedin)
SEQUENCE
Proprietary complex
CAS
Not assigned
EU STATUS
Research only
WADA
Not listed
MIN PURITY
Lab-specific
Khavinson Bioregulators

Suprefort — EU research guide.

Suprefort is a Khavinson-series peptide bioregulator derived from pancreatic tissue, proposed to support beta-cell gene regulation and pancreatic reserve in aging models. It is the natural-complex counterpart to Pancragen, the synthetic tetrapeptide in the same research family.

Last reviewed:

What is Suprefort?

Suprefort is a Khavinson-series peptide bioregulator derived from pancreatic tissue, proposed to support beta-cell gene regulation and pancreatic reserve in aging models. It is the natural-complex counterpart to Pancragen, the synthetic tetrapeptide in the same research family.

What does the research show?

Available data is limited to one small, non-peer-reviewed institutional report from the originating research group and in-vitro work on the related tetrapeptide Pancragen; no animal study naming Suprefort was found. No independently replicated controlled trials are publicly available as of mid-2026.

EU legal status

Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.

⚠ Not a substitute for established metabolic or diabetes research compounds — the evidence here is preliminary and from a narrow research lineage.
✓ Not yet tracked in PeptideCompare's price comparison. Verify any vendor's COA and sequence/identity claims directly before ordering — see our COA guide.
EVIDENCE SUMMARY
NO HUMAN DATA
Peer-reviewed data on Suprefort itself — Searches of the indexed literature found no peer-reviewed human or animal study that names Suprefort. Any link between the brand and published experiments rests on vendor statements, and the composition of the pancreas polypeptide complex is not given in a source I could verify.
LIMITED
Vendor-hosted institutional report (34 patients) — A report from the originating group's medical centre describes 34 patients (12 with latent chronic pancreatitis, 22 with latent type 2 diabetes) in 2003-2004 and mentions improved appetite, less dyspepsia and lower glucose values in a glucose tolerance test. It is not peer reviewed, not independent and not replicated.
LIMITED
Related synthetic tetrapeptide Pancragen, cell culture only — For the tetrapeptide Lys-Glu-Asp-Trp-NH2 (Pancragen), the same group reports in aged human pancreatic cell cultures higher expression of proliferation and protective markers (Ki67, PCNA, MMP2, MMP9, Mcl-1) and lower p53, and higher differentiation-factor expression in acinar and islet cells. These are in-vitro marker results, not clinical outcomes, and not Suprefort.

Molecular information

CAS number
Not assigned

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Potency retained over time

Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.

Freezer −20 °C
36+ mo
Stable · >95% potency
Fridge 4 °C
4-5 wks
In use · after recon
Room 20 °C
5-6 days
Avoid · increased loss
Warm 37 °C+
<1 day
Critical · rapid degradation

⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.

Suprefort is not yet in our price comparison

We expand EU supplier coverage every month.

References

  1. In-vitro study of the synthetic tetrapeptide Lys-Glu-Asp-Trp-NH2 in aged human pancreatic cell cultures; expression of several markers shifted. It concerns Pancragen, not Suprefort, and sample size is not given in the abstract. Khavinson VKh, Sevostyanova NN, Durnova AO, Linkova NS, Tarnovskaya SI, Dudkov AV, Kvetnaya TV. Tetrapeptide stimulates functional activity of pancreatic cells in aging. Adv Gerontol. 2013;3(3):220-224. DOI
  2. In-vitro study of Pancragen on differentiation markers in ageing pancreatic acinar and islet cells. Again the related tetrapeptide and marker expression only, with no clinical or glucose outcome. Khavinson VK, Durnova AO, Polyakova VO, et al. Effects of Pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med. 2013;154:501-504. DOI
  3. Institutional report of the group's own medical centre in 34 patients with latent chronic pancreatitis or type 2 diabetes. Listed only to show what human data exist; it is not peer reviewed, not independent and hosted by a vendor. Khavinson V. Clinical study results of peptide bioregulator Suprefort (institutional report of the medical center of the St Petersburg Institute of Bioregulation and Gerontology; 34 patients, 2003-2004). Hosted on a vendor website, undated, not peer reviewed. Source

Related guides

Khavinson Bioregulators

Bolamin
Khavinson Bioregulators

Bronchogen
Khavinson Bioregulators

Cardiogen
PeptideCompare AssistantOnline · replies instantly
Hi! I help you quickly find the right page — about legality, COAs, badges or suppliers. No price advice, no dosing.
Try a question
Find a supplier Questions about a peptide? Read our articles Compare prices Is this legal in the EU? How to read a COA What do badges mean? Will customs stop my order? What is BAC water? Talk to a doctor first?
Navigation assistant · no medical advice